Marshall Wace, LLP Bausch Health Companies Inc. Transaction History

Marshall Wace, LLP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$5.72 - $8.8 $404,913 - $622,943	-70,789 Reduced 55.58%	56,586 $452,000
Q1 2023 May 15, 2023	BUY	$6.28 - $9.85 $799,915 - $1.25 Million	127,375 New	127,375 $1.03 Million
Q3 2022 Nov 14, 2022	BUY	$4.58 - $9.21 $3.38 Million - $6.8 Million	738,849 New	738,849 $5.09 Million
Q2 2022 Aug 15, 2022	SELL	$7.06 - $23.63 $2.17 Million - $7.28 Million	-307,874 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$21.6 - $27.79 $6.65 Million - $8.56 Million	307,874 New	307,874 $7.04 Million
Q1 2021 May 17, 2021	SELL	$21.37 - $34.38 $2.14 Million - $3.45 Million	-100,311 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.31 - $21.12 $1.54 Million - $2.12 Million	100,311 New	100,311 $2.09 Million
Q3 2020 Nov 16, 2020	SELL	$14.88 - $20.13 $2.02 Million - $2.73 Million	-135,716 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$13.31 - $20.51 $1.81 Million - $2.78 Million	135,716 New	135,716 $2.48 Million
Q3 2019 Nov 14, 2019	SELL	$20.88 - $25.66 $1.1 Million - $1.35 Million	-52,529 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$20.52 - $26.45 $1.08 Million - $1.39 Million	52,529 New	52,529 $1.33 Million
Q1 2019 May 14, 2019	SELL	$20.23 - $26.29 $7.46 Million - $9.69 Million	-368,526 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$17.64 - $28.32 $6.5 Million - $10.4 Million	368,526 New	368,526 $6.81 Million
Q3 2018 Nov 14, 2018	SELL	$20.64 - $25.67 $2.64 Million - $3.28 Million	-127,873 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$15.07 - $26.86 $1.93 Million - $3.43 Million	127,873 New	127,873 $2.97 Million

254

253M

5.53M

16.5M

Ticker BHC
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 361,728,000
Market Cap $2.67B
Description
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, O...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.